Ibandronate (as sodium) 3mg/3mL; soln for IV inj. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone ...

An investigational nondaily oral ibandronate regimen (20 mg of ibandronate every other day for 12 doses every 3 months) demonstrated antifracture efficacy, [16] fueling the search for extended ...

as shown by meta-analyses stratified by ibandronate dose (annual cumulative exposure). Intermittent and monthly oral risedronate have shown bone density gains similar to those seen with daily oral ...